January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

September 16, 2014

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.

September 5, 2014

Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.

September 5, 2014

Purdue Pharma on Thursday presented results from two epidemiological studies evaluating the reformulation of OxyContin. 

August 25, 2014

DSN presents a preview of some of the hottest beauty products that appear on the show floor at NACDS Total Store Expo.

August 25, 2014

DSN presents a preview of some of the hottest OTC products that appear on the show floor at NACDS Total Store Expo.

August 25, 2014

DSN presents a preview of some of the hottest pharmacy and technology products that will appear on the show floor at NACDS Total Store Expo.

August 23, 2014

DSN presents a preview of some of the hottest beauty products that appear on the show floor at NACDS Total Store Expo.

August 23, 2014

DSN presents a preview of some of the hottest OTC products that appear on the show floor at NACDS Total Store Expo.

August 22, 2014

DSN presents a preview of some of the hottest general merchandise and consumables products that will appear on the show floor at NACDS Total Store Expo.

August 22, 2014

DSN presents a preview of some of the hottest pharmacy and technology products that will appear on the show floor at NACDS Total Store Expo.

August 20, 2014

DSN presents a preview of some of the hottest beauty products that will appear on the show floor at NACDS Total Store Expo.

August 19, 2014

DSN presents a preview of some of the hottest OTC products that will appear on the show floor at NACDS Total Store Expo.

August 14, 2014

Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.

August 5, 2014

Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration.

July 24, 2014

The Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), a long-acting opioid analgesic.

July 17, 2014

Purdue Pharma announced that the Food and Drug Administration approved a new 7.5-mcg/hour dosage strength of Butrans (buprenorphine) transdermal system CIII.